Accompanying the recent TIL trial results published by the Netherands Cancer Institute in the NEJM, Pr Coukos authors the journal's editorial: TIL Therapy Entering the Mainstream.
This editorial by George Coukos accompanies the publication* by the NEJM of the Netherland Cancer Institute's latest TIL trial, led by Pr. John Haanen.
*Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma